Laurus Labs Ltd
NSE:LAURUSLABS

Watchlist Manager
Laurus Labs Ltd Logo
Laurus Labs Ltd
NSE:LAURUSLABS
Watchlist
Price: 859.7 INR -0.4% Market Closed
Market Cap: 464.1B INR

Gross Margin
Laurus Labs Ltd

56.5%
Current
52%
Average
48.5%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
56.5%
=
Gross Profit
33.5B
/
Revenue
59.3B

Gross Margin Across Competitors

Country Company Market Cap Gross
Margin
IN
Laurus Labs Ltd
NSE:LAURUSLABS
464.5B INR
57%
US
Eli Lilly and Co
NYSE:LLY
635.2B USD
83%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
56%
US
Johnson & Johnson
NYSE:JNJ
419B USD
68%
CH
Roche Holding AG
SIX:ROG
198.6B CHF
74%
UK
AstraZeneca PLC
LSE:AZN
178.6B GBP
82%
CH
Novartis AG
SIX:NOVN
190.2B CHF
76%
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK
84%
US
Merck & Co Inc
NYSE:MRK
209.3B USD
78%
IE
Endo International PLC
LSE:0Y5F
183.4B USD
68%
US
Pfizer Inc
NYSE:PFE
141.9B USD
74%

Laurus Labs Ltd
Glance View

Laurus Labs Ltd., an Indian pharmaceutical powerhouse, has etched its presence in the global pharma industry with a focus on delivering affordable and high-quality active pharmaceutical ingredients (APIs). Founded in 2005, the company's trajectory has been nothing short of remarkable, with an emphasis on research-driven production and sustainability. The Hyderabad-based conglomerate cultivates its core expertise within key therapeutic areas such as antiviral, cardiovascular, and oncology medications. By amalgamating scientific prowess with cutting-edge manufacturing facilities, Laurus Labs has positioned itself as a fundamental supplier in the fight against global ailments, providing APIs to some of the most critical generic pharmaceuticals worldwide. The company's commitment to health innovation is reflected in its robust portfolio of over 60 commercialized APIs, substantiating its pivotal role in the pharmaceutical supply chain. Adding another feather to its cap, Laurus Labs has ventured into the formulation business, manufacturing finished dosage forms that reach consumers directly. This vertical integration allows Laurus to capture a larger share of the pharmaceutical value chain, maximizing returns from its research and manufacturing capabilities. The company's foray into generic formulations has opened doors to new markets, particularly in challenging economies where cost-effective treatment is crucial. By leveraging its API expertise to produce effective, high-quality generic medications, Laurus Labs not only enhances its profitability but also adheres to its founding ethos of making healthcare accessible. With investments in research and development and a commitment to expanding its product line, Laurus Labs continues to strengthen its presence while nurturing partnerships globally, fueling its growth trajectory.

LAURUSLABS Intrinsic Value
512.93 INR
Overvaluation 40%
Intrinsic Value
Price
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
56.5%
=
Gross Profit
33.5B
/
Revenue
59.3B
What is the Gross Margin of Laurus Labs Ltd?

Based on Laurus Labs Ltd's most recent financial statements, the company has Gross Margin of 56.5%.

Back to Top